Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Beyond Air ( (XAIR) ) has shared an update.
On January 14, 2026, Beyond Air entered into a securities purchase agreement with an institutional investor for a $5 million private placement priced at-the-market under Nasdaq rules, comprising 524,990 shares of common stock, pre-funded warrants for up to 3,405,828 additional shares and common warrants for up to 3,930,818 shares, with the offering closing on January 16, 2026. The unregistered transaction, for which Rodman & Renshaw acted as placement agent, includes immediate exercisability of the warrants subject to ownership caps and anti-dilution adjustments, imposes near-term restrictions on additional equity issuance and variable-rate financings, and is supported by a registration rights agreement requiring Beyond Air to register the resale of the issued shares and warrant shares, with the company planning to use the net proceeds for working capital and general corporate purposes.
The most recent analyst rating on (XAIR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Spark’s Take on XAIR Stock
According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.
The score is held down primarily by very weak profitability, high leverage/negative ROE, and challenging cash-flow trends. Offsetting this are improving near-term technical momentum and a more positive operational narrative from the earnings call (strong YoY growth, lower burn), supported by recent financing and leadership updates, but these positives do not yet overcome the underlying financial strain.
To see Spark’s full report on XAIR stock, click here.
More about Beyond Air
Beyond Air, Inc., based in Garden City, N.Y., is a commercial-stage medical device and biopharmaceutical company focused on harnessing endogenous and exogenous nitric oxide to treat respiratory illnesses, neurological disorders and solid tumors. The company’s first system, LungFit PH, has received FDA approval and a CE Mark for treating term and near-term neonates with hypoxic respiratory failure, and Beyond Air is advancing additional LungFit systems in clinical trials for severe lung infections such as viral community-acquired pneumonia, including COVID-19, and nontuberculous mycobacteria, while its affiliate Beyond Cancer, Ltd. is investigating ultra-high concentration nitric oxide therapies for certain solid tumors in pre-clinical studies.
Average Trading Volume: 7,690,102
Technical Sentiment Signal: Sell
Current Market Cap: $13.62M
Find detailed analytics on XAIR stock on TipRanks’ Stock Analysis page.